

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/060583 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) *A61K 31/433* (2006.01)
A61K 31/381 (2006.01) *A61K 31/496* (2006.01)
A61K 31/404 (2006.01) *A61K 31/50* (2006.01)
A61K 31/4196 (2006.01) *A61K 31/5375* (2006.01)
A61K 31/421 (2006.01) *A61K 31/7064* (2006.01)
A61K 31/426 (2006.01)

(21) International Application Number:

PCT/US2021/048960

(22) International Filing Date:

03 September 2021 (03.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/074,045 03 September 2020 (03.09.2020) US
63/135,023 08 January 2021 (08.01.2021) US
63/172,791 09 April 2021 (09.04.2021) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, California
94063 (US).

(72) Inventors: **AHLER, Ethan**; 700 Saginaw Drive, Redwood
City, California 94063 (US). **STAHLHUT ESPINOSA,**
Carlos Ernesto; 700 Saginaw Drive, Redwood City, Cal-
ifornia 94063 (US). **MONTGOMERY, David Church**;
700 Saginaw Drive, Redwood City, California 94063 (US).
QUINTANA, Elsa; 700 Saginaw Drive, Redwood City,
California 94063 (US). **WILDES, David E.**; 700 Saginaw
Drive, Redwood City, California 94063 (US). **LEE, Grace**
J.; 700 Saginaw Drive, Redwood City, California 94063
(US). **TOVBIS SHIFRIN, Nataliya**; 700 Saginaw Drive,
Redwood City, California 94063 (US).

(74) Agent: **ALLEN, Derick E.** et al.; Armstrong Teasdale LLP,
7700 Forsyth Boulevard, Suite 1800, St. Louis, Missouri
63105 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS

(57) Abstract: Methods are provided herein for treating a subject having a disease or disorder associated with cells having a SHP2 mutation, e.g., an activating SHP2 mutation. The SHP2 mutation may cause resistance to a SHP2 inhibitor, e.g., an allosteric SHP2 inhibitor. Methods herein provide administering to the subject a therapeutically effective amount of a SOS1 inhibitor alone or in combination with an additional therapeutic agent.

WO 2022/060583 A1